Get started
BIONTECH SEBIONTECH SEBIONTECH SE

BIONTECH SE

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

BNTX/N trade ideas

VIR & BNTX: 2 Covid stocks at decision pointsBoth VIR and BNTX show similar price action since their respective Covid related drug announcements which put in their March highs. Both stocks have been consistently supported by their VWAP from IPO and their 50 day EMAs. Both stocks also remain held down by their VWAP from their March highs. With both stocks approaching the apex of their descending triangles, I anticipate price needs to expand in one direction or the other. I anticipate both stocks break higher on renewed Covid concerns/media coverage. If you were to take a look at CEMI/GNMK/AYTU/NNVC/IBIO, to name a few, these Covid related names look like they are ready to reverse to the upside after consolidating throughout the market's rally off the lows. It is interesting that with the selloff we saw this past week, some of these Covid stocks seemed to turn the corner. Disclosure: I own both BNTX and VIR
NASDAQ:BNTXLong
by ETrades1
Pfizer and BioNTech Dose First Participants in the U.S. Hey fellow Traders from TradingView, this is an update to the actual Situation and my previous Analysis If you agree with my Analysis or find it useful , please leave me a like for my work it would be greatly appreciated. Im still bullish and optimistic that BNTX participation will have a huge global impact. The stock seems to be news related, so expect it to make huge moves when they finally will announce to have completed those first worldwide clinical studies. The Moving Averages are lining up and signalizing us there will soon be a Price expansion. Assuming the 55 MA line serves as a support we cacn expect the stock to bounce off that and rise to the resistance battleground area. I´d place my Stop Loss below the next support pivot at either 36.85 to not risk gettiong shaken out before the upcoming outbreak. If you can handle that amount of risk. If not a LOD SL is always a great way to reduce risk. Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. This U.S. trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week. "The Phase 1/2 study is designed to determine the safety, immunogenicity and optimal dose level of four mRNA vaccine candidates, and is to be evaluated in a single, continuous study. The dose level escalation portion (Stage 1) of the Phase 1/2 trial in the U.S. will enroll up to 360 healthy subjects into two age cohorts (18-55 and 65-85 years of age). The first subjects immunized in Stage 1 of the study will be healthy adults 18-55 years of age. Older adults will only be immunized with a given dose level of a vaccine candidate once testing of that candidate and dose level in younger adults has provided initial evidence of safety and immunogenicity. Sites currently dosing participants include NYU Grossman School of Medicine and the University of Maryland School of Medicine. The University of Rochester Medical Center/Rochester Regional Health and Cincinnati Children’s Hospital Medical Center will begin enrollment shortly." Source by: NASDAQ:BNTX FWB:22UA investors.biontech.de Remember, this is only my opinion after considering all facts and informing myself about the Up/Downside of this stock. So no financial advise is given here. Always do your own reasearch. Thank you for taking the time and i hope to see you again in my next post! See you there Sincerly, Sebastian - TradingExperts Europe
NASDAQ:BNTXLong
by Sebastian-TradingExpertsEU
6
Biontech AG Outbreak - First COVID-19 human vaccine trial test Hey fellow Trader, The uprising Biotechnology company from NASDAQ:BNTX Mainz, Germany is on its final steps from developing a vaccine for the actual Bio-weapon health crisis from the "new flu" . With Rolf Zinkernagel a brilliant Scientiests that can proudly say to win a nobelprice and a strong financial background , from big names in the Pharmaceutical field. When BioNTech AG announced to start with the first human vaccine tests after getting an approval in Europa , a US approval should follow shortly after also. We should expect News from those test in end May/june and if they´ve managed to create a proven vaccine afterwards im staying LONG in this Outbreak because its Trending and the Chances are high for a good R/R. A Golden Cross is forming and the Overall Stock is positive and with a low beta so less correlation risk in this given "Crazy Market" . So with a break of the 56 level we should see a strong move up. Goals are high and i think it could touch the 100 mark again with reactive move down to given support levels if they arent successful with their vaccine Therapy. STOPLOSS tight at 49,45 I hope this was helpful but it only displays my opionion and no financial adivce is given here. Sincerly, Sebastian
NASDAQ:BNTXLong
by Sebastian-TradingExpertsEU
1